Biotechs are having a field day on Wall Street as every day, a new 100% gain is coming across our desks. The unrealistic gains highlight just how unique the current bear market is. Mainly because a worldwide pandemic is not the typical root cause of financial crises. From the oil recession in 1973 to extreme […]
Category Archives: Pharmaceutical and Biotechnological Stocks
ABIO skyrockets 225% today on COVID-19 treatment – have all the gains been made?
An important lesson to understand in investing is that buyers invest in what they believe to be true even if it is false. Biotechs popping up every second and developing a possible COVID-19 treatment is a perfect example. Many investors buy into the biotech on the belief that the company could develop a viable treatment. […]
Mersana Therapeutics reports positive cancer drug results – causing uncontrolled buying.
A cure for cancer is the most desirable statement for scientists and investors alike. However, optimism is often met with disappointment as the task of curing cancer is no easy feat. Despite the difficulty, the scientific world continues to develop drug after drug in an attempt to eradicate the horrific group of diseases. Despite a […]
Novavax’s COVID-19 vaccine enters Phase 1 trials – is Moderna in trouble?
A vaccine is an unlikely solution. However, biotechs often tirelessly work on vaccines even after the expiration date of a virus. For example, vaccines for ebola, Zika, and Sars2 are still in development. Thus if a vaccine is unattainable before COVID-19 fizzles out, biotechs will continue to create a vaccine. Because we do not want […]
Evofem skyrockets after the FDA approves its birth control gel.
Why did the stock rise? Evofem made headlines after the FDA approved Evofem’s (NASDAQ: EVFM) new birth control gel “Phexxi.” Phexxi is an applicator that women insert before sex to prevent pregnancy. The FDA approved the drug through Phase 3 clinical trial, enrolling tests of 1,330 women. Evofem achieved an efficacy rate of 86.3%, which […]
Chinese company shows early signs of promising COVID-19 vaccine.
The vaccine race involves many runners, with the leaders being Moderna (NASDAQ: MRNA), Inovio (NASDAQ: INO), and Novavax (NASDAQ: NVAX). It feels like many vaccine companies are sprinting as they accelerate through the clinical timeline. However, the US government raised the stakes on Thursday when they announced a $1.2 billion injection into AstraZene’s untried vaccine. […]
Potential FDA approval sees Seneca surge 100+%
Seneca Biopharma (NASDAQ: SNCA) came out of the markets storming 100% higher today at $1.67. The volcanic surge is off the back on no news, leaving investors confused. SNCA forums on Yahoo Finance and Stockwits are flooded with the same question “why is SNCA up”? Why is Seneca surging? The unsureness of why SNCA is […]
Novavax look to repeat last week’s 120% gain.
Novavax (NASDAQ:NVAX) look to surge come market open with pre-market up 13% (at the time of writing). Novavax captured the wallets of investors last week when they received $384 million in vaccine funding from CEPI. This week NVAX is expected to captivate investors with a new all-time-high. Which seems achievable, especially if last week’s insane […]
Moderna set to surge after producing positive trial results for COVID-19 vaccine
Moderna announced this morning that their interim Phase 1 data for COVID-19 vaccine has shown positive results. The company has been heavily watched by investors and speculators alike – as their vaccine (mRNA-1273) continues to show positive signs. The announcement confirmed the Biomedical Advanced Research and Development Authority (BARDA) are in support of the companies phase […]
Mesoblast set to surge off COVID-19 stem cell trials.
The world is in dire need of a COVID-19 treatment. A vaccine is the plan b for the long-term. However, governments can take action immediately through COVID-19 treatments and testing. Mesoblast (NASDAQ:MESO) and (ASX:MSB), an Australian biotech is developing a stem cell treatment (Remestemcel-L), for COVID-19. The primary reason people die from COVID-19 is due […]
Novavax look to be the COVID-19 vaccine winner after surging 120%.
Novavax (NASDAQ:NVAX) is set to surge come market open with pre-market up 13% (at the time of writing). Novavax captured the wallets of investors last week when they received $384 million in vaccine funding from CEPI. This week NVAX is expected to captivate investors with a new all time-high. Which seems achievable especially if last […]
Here’s why Clinuvel could skyrocket this week?
Clinuvel (ASX: CUV), arguably one the best biotechs on the market, is trading at 35-40% of its true value (based on my research, not advice). CUV specialise in treating patients who suffer from severe skin disorders. If the name CUV or Clinuvel sounds foreign, then I suggest reading our digestible, free and extensive report here. […]
How Gilead drove a US rally based on optimism.
The Dow Jones rallied upwards of 700 points on Friday as Gilead’s (NASDAQ:GILD) “Wonder Drug” has shown promising results according to a Chicago University source. The video of Infectious Disease Professor Kathleen Mullane, goes into some detail over the success of Remdesivir in recent trials with patients reporting fast recoveries from COVID-19. Now if you […]
BREAKING: NASDAQ stock shows “100% survival rate” on new COVID-19 treatment
Pluristem Therapeutics Inc. (NASDAQ: PSTI) has made groundbreaking progress in the treatment for COVID-19 in treating severely ill patients. Pluristem uses PLX stem therapy on patients that have critical complications due to COVID-19. The Israeli based biotech released a statement on Monday : confirming they had been cleared by the FDA to proceed with the […]
Does JNJ’s COVID-19 vaccine and 6.3% dividend boost make them a recession-proof stock?
What do Listerine, baby powder, and band-aids all have in common? All of these household products are part of the pharmaceutical conglomerate Johnson and Johnson (NYSE: JNJ). It appears that the pharmaceutical mammoth is immune to the pandemic. While airlines, cruise ships, and travel agents are being hammered, JNJ is almost at a full V […]
WORX makes breakthrough deal on COVID-19 testing – is it too late to invest?
SCworx Corp (WORX: NASDAQ) had a historical day yesterday opening from $2.25 and catapulting itself to highs of $14.00 before closing the ride at $12.02. It is remarkably rare to see gains at this level over one day. The sublime increase came after Scworx Corp announced they had received a purchase “provision” for 48 million […]
If Mesoblast develops a COVID-19 vaccine, could they become the next CSL?
The world needs a vaccine. Because people want their quality of life to return to normal. People do not want to continue entertaining the idea of COVID-19 taking away their loved ones. Our demand for a cure is sparking a drug development frenzy in the biotech sphere. A tsunami of biotechs are now in the […]
Could ZNO skyrocket as the Coronavirus escalates?
The number of Coronavirus cases crosses 100,000, stocks plummet to multi-year record lows on the Black Monday of 2020, and Italy is forced into lockdown. Pretty grimm news for people around the world, investors and governments. Just when we thought things could not get any worse the World Health Organisation (WHO) labelled the Coronavirus a […]
Everything you need to know before investing in PAR and CUV during the coronavirus.
Are you frustrated with the market acting like a rollercoaster? If yes, then you are not alone. Many smart investors, have had enough with the media suffocating the public on the coronavirus. Many investors are now basing their entire financial decision on what the media reports. Consequently, the coronavirus fear is beating down fundamentally strong […]
Everything you need to know about iBio before investing.
IBio Inc (NYSE:IBIO) is a Texas based Bio-Pharmaceutical company which has seen a recent surge of 720% in 2020 alone. The recent Coronavirus scare has led investors to divert their capital into Bio-pharma stocks such as iBIO, due to the companies efforts in developing a vaccine to control the virus. In early February, the company announced […]